GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (MEX:ROG N) » Definitions » 3-Year Sharpe Ratio

Roche Holding AG (MEX:ROG N) 3-Year Sharpe Ratio : -0.31 (As of Jun. 27, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Roche Holding AG 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-06-27), Roche Holding AG's 3-Year Sharpe Ratio is -0.31.


Competitive Comparison of Roche Holding AG's 3-Year Sharpe Ratio

For the Drug Manufacturers - General subindustry, Roche Holding AG's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's 3-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's 3-Year Sharpe Ratio falls into.


;
;

Roche Holding AG 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Roche Holding AG  (MEX:ROG N) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Roche Holding AG 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG Headlines

No Headlines